|
|
SLA-AF |
|
Vaxjo ID |
192 |
|
Vaccine Adjuvant Name |
SLA-AF |
|
Adjuvant VO ID |
VO_0005482
|
|
Description |
aqueous formulation (AF) of a chemically synthesized toll-like receptor (TLR)-4 agonist, second-generation lipid adjuvant (SLA) that induces Th1 response |
|
Stage of Development |
Research |
|
Location Licensed |
US (AAHI) |
|
Host Species for Testing |
3 |
|
Components |
second generation lipid adjuvant |
|
Storage |
2-8C |
|
Preparation |
solubilize in micellar aqueous formulation |
|
Function |
TLR4 engagement through modifications to the acyl chains |
| References |
(Soza, 2024): Vaccine Adjuvant Compendium - VAC [https://vac.niaid.nih.gov/view?id=72]
Nam et al., 2022: Nam HJ, Hong SJ, Lee A, Kim J, Lee S, Casper C, Carter D, Reed SG, Simeon G, Shin EC. An adjuvanted zoster vaccine elicits potent cellular immune responses in mice without QS21. NPJ vaccines. 2022; 7(1); 45. [PubMed: 35459225].
Poncet et al., 2020: Poncet D, Hessler C, Liang H, Gautheron S, Sergent M, Rintala ND, Seydoux E, Huang PD, Argilla D, Ruiz S, Heinrichs J, Maciel M Jr, Orr MT. Preclinical optimization of an enterotoxigenic Escherichia coli adjuvanted subunit vaccine using response surface design of experiments. NPJ vaccines. 2020; 5; 83. [PubMed: 32983577].
|
|
